Huadong Medicine stock: Nine-month profit reaches RMB 2.772 billion

Published on 10/30/2026 at 02:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Huadong Medicine stock posted higher nine-month revenue and earnings, according to RTT News. Revenue reached RMB 33.019 billion for the period.

Neunmonatszahlen zeigen moderates Wachstum

Der Umsatz stieg im Neunmonatszeitraum auf RMB 33,019 Milliarden.
Der Gewinn je Aktie erhöhte sich auf RMB 1,5806 gegenüber RMB 1,5666 im Vorjahr.

Huadong Med, CNE0000011S1, Illustration mit AI erstellt.

Huadong Medicine stock is in focus after the company reported higher earnings for the first nine months of 2026. According to RTT News, net profit reached RMB 2.772 billion, compared with RMB 2.748 billion in the same period a year earlier.

Revenue growth remains limited

Revenue for the nine-month period rose to RMB 33.019 billion from RMB 32.664 billion. That represents growth of 1.1 percent year over year, indicating a modest top-line increase alongside the profit improvement.

Reported earnings per share were RMB 1.5806, up from RMB 1.5666 a year earlier. The figures are reported on a GAAP basis in the RTT News summary and should be assessed alongside the company's product mix, operating costs and investment in new medicines.

Investor context

The result provides a current operating update for Huadong Medicine, but the reported increase alone does not establish a cause for any share-price movement. Investors may wish to monitor subsequent disclosures on innovative medicines, commercialisation and medical aesthetics, which can affect the mix and profitability of the business.